* Esperion Therapeutics Inc ESPR.OQ reported a quarterly
adjusted loss of 15 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -37 cents. The mean expectation of
seven analysts for the quarter was for a loss of 18 cents per
share. Wall Street expected results to range from -22 cents
to -11 cents per share.
* Revenue rose 52% to $51.63 million from a year ago;
analysts
expected $51.32 million.
* Esperion Therapeutics Inc's reported EPS for the quarter
was a
loss of 15 cents.
* The company reported a quarterly loss of $29.52 million.
* Esperion Therapeutics Inc shares had risen by 33.9% this
quarter and lost 26.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 57.6%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Esperion
Therapeutics Inc is 6.50
This summary was machine generated from LSEG data November 7 at
02:47 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.18 -0.15 Beat
Jun. 30 2024 -0.18 -0.33 Missed
Mar. 31 2024 0.05 0.34 Beat
Dec. 31 2023 -0.48 -0.50 Missed